ThromboGenics NV Announces Business Update and Half Year Re...((1706) (1212) Selling expen...)

Date:8/27/2009

(1,706) (1,212) Selling expenses (223) (222) Other operating income 2,092 33 OPERATING RESULT (5,524) 17,286 Financial income 1,033 1,022 Financial expenses (179) (190) Result before income tax (4,670) 18,118 Income tax 7 (90) Net result for the period (4,663) 18,028 Attributable to: Equity holders of the company (4,663) 18,028 Result per share Basic earnings per share {Euro} (0.18) 0.72 Diluted earnings per share {Euro} (0.17) 0.67 Unaudited consolidated statement of comprehensive income ThromboGenics Unaudited consolidated statement of other comprehensive income Half year Half year In '000 Euro - According to IFRS 6 months 6 months Jan - June 2009 Jan - June 2008 Available-for-sales investments Valuation gain/(loss) taken to equity 72 (58) Exchange differences on translation of foreign operations 11 4 Other comprehensive income net of tax 83 (54) Total result for the period (4,663) 18,028 Total comprehensive income (4,580) 17,974 Attributable to: Equity holders of the parent (4,580) 17,974 Unaudited consolidated statement of financial position ThromboGenics
'/>"/>

SOURCE ThromboGenics NV Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results